Video

Dr. Hutson on the future of the advanced renal cell carcinoma treatment paradigm

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting

“The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies,” says Thomas E. Hutson, DO, PharmD, FACP.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Thomas E. Hutson, DO, PharmD, FACP, shares his vision for the future of patient treatment in the field of advance renal cell carcinoma (RCC).Hutson is the director of the urologic oncology program at Baylor University Medical Center in Dallas, Texas.

      Transcript

      The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies. And I hope that we move forward with different biomarkers that will help us separate certain patient groups out so that they can receive the best, and I'll put in quotation marks “targeted therapies,” to give them the best outcome with the least side effects. So, we're recognizing that that one person's kidney cancer is not the same as the other’s. And it's time now that we can apply all the advances across the cancer spectrum in general to kidney cancer.

      Transcript has been edited for clarity.

      Related Videos
      Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
      Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Jason Hafron, MD, considers the future for AI in urology
      Jason Hafron, MD, considers the future for AI in urology
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Investigators evaluate tamsulosin use in pediatric patients
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
      Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      How recombinant BCG could ease strain of supply issues
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Related Content
      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
      February 20th 2025

      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

      Thomas E. Hutson, DO, PharmD
      "The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
      Former MLB player Dave Winfield shares lessons from baseball, philanthropy
      November 15th 2024

      Former MLB player Dave Winfield shares lessons from baseball, philanthropy

      Urology Times staff
      In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
      February 18th 2025

      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

      Hannah Clarke
      However, the triplet regimen did not lead to an improvement in overall survival.
      blurred photo of a clinic hallway
      May 28th 2023

      2023 AUA highlights in benign urology

      Urology Times staff
      Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
      Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
      February 16th 2025

      Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

      Benjamin P. Saylor
      "The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
      Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
      February 15th 2025

      Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

      Benjamin P. Saylor
      ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.
      © 2025 MJH Life Sciences

      All rights reserved.